tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Cabaletta Bio: Promising Clinical Progress and Strategic Advancements Drive Buy Rating
PremiumRatingsCabaletta Bio: Promising Clinical Progress and Strategic Advancements Drive Buy Rating
4M ago
Cabaletta Bio reports Q3 EPS (44c), consensus (46c)
Premium
The Fly
Cabaletta Bio reports Q3 EPS (44c), consensus (46c)
4M ago
Cabaletta Bio sees cash runway into 2H26
Premium
The Fly
Cabaletta Bio sees cash runway into 2H26
4M ago
Cabaletta Bio’s Innovative Myopathy Study: A Potential Game-Changer?
PremiumCompany AnnouncementsCabaletta Bio’s Innovative Myopathy Study: A Potential Game-Changer?
4M ago
Cabaletta Bio’s Promising SLE Study: A Potential Game-Changer?
Premium
Company Announcements
Cabaletta Bio’s Promising SLE Study: A Potential Game-Changer?
4M ago
Cabaletta Bio’s Promising Study on CABA-201 for Systemic Sclerosis: A Market Perspective
Premium
Company Announcements
Cabaletta Bio’s Promising Study on CABA-201 for Systemic Sclerosis: A Market Perspective
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100